Loading
The Johns Hopkins blood test that first showed one draw could find several cancers and point to the organ; its approach passed to Thrive Earlier Detection and then to Exact Sciences, whose Cancerguard test followed.
CancerSEEK was developed at Johns Hopkins. In the 2018 Science paper (Cohen et al.) it was positive in a median of 70% of 1,005 patients with eight non-metastatic cancer types, with specificity above 99% (7 of 812 healthy controls positive), and localised the cancer to a small number of sites in a median of 83% of patients. In DETECT-A (Lennon et al., Science 2020), a version of the test combined with PET-CT screened 10,006 women aged 65 to 75: 26 cancers were detected by blood testing, 1% of participants had PET-CT after a false-positive blood test and 0.22% a futile invasive procedure.
Thrive Earlier Detection, which licensed the approach, was acquired by Exact Sciences on 5 January 2021 (Exact Sciences 10-Q). Exact's ASCEND study (NCT04213326) collected samples for the test's development. The commercial successor, Cancerguard, reads DNA methylation and proteins rather than mutations and proteins, so CancerSEEK's figures do not transfer to it.
Mutations in 16 genes in cell-free DNA plus eight circulating proteins, combined by a classifier that also localises the likely organ.
1.CancerSEEK slips into a pocket on its target.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
A blood test can find early, treatable cancers in people who feel well, including cancers for which no screening exists. It is not a replacement for mammography or colonoscopy but a possible addition. Larger randomised trials are needed to show benefit outweighs harm.
The proof of principle for multi-cancer blood tests that include pancreas; the sensitivity figures come from known cancers, not from screening.
Query for this drug: (TITLE:"CancerSEEK" OR ABSTRACT:"CancerSEEK") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CancerSEEK, not a curated reading list.
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Proteomics & phosphoproteomics, Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA) and the tags test, mced.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/